Andy Davidson has created the Nova Co-foundery to help develop businesses from before day one.
In this episode of The EIS Navigator, Brian and Andy discuss how the Co-foundery works and how he developed his company-building philosophy.
As well as his practical experience, Andy has extensively researched the issues that startups have. A significant focus is the five reasons that startups fail (100firsthits.com). We discuss what these are, why they are a problem and how Nova works to avoid them.
This is the first of a two-parter – we were having such conversation we kept going longer than usual. In the next episode we turn our attention to the EIS industry.
Please email [email protected] if you have any questions or comments on The EIS Navigator.
Never miss an episode – click here to subscribe to The EIS Navigator on most popular services.
Read Hardman & Co’s latest investment research on Nova funds here.
Visit the Nova website here.
The Lean Startup – Eric Ries
Crossing the Chasm – Geoffrey Moore
The Four Steps to the Epiphany – Steve Blank
Andy Davidson is the Director and CEO of Nova. He has a background in technology and finance, and over the last five years as CEO of Nova he has co-founded, invested in and raised investment for over 80 digital technology startups.
Disclaimer
Please note this podcast/interview does not constitute a financial promotion and is provided for informational purposes and should not be construed as an invitation or offer to buy or sell any investments. Please be aware that investments into unquoted companies are high risk, long term and illiquid investments. Your capital is at risk. Past performance is not a reliable indicator of future performance. Target returns are not guaranteed and forward looking statements are illustrative only and must not be relied upon. Investors should only invest on the basis of reading the full offer documentation. Listeners must make their own independent decisions and obtain their own independent advice regarding any information, projects, securities, tax treatment or financial instruments mentioned herein.
